# Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

> **NCT00876486** · PHASE3 · COMPLETED · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 213 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Genexol-PM®
- **DRUG:** Genexol®

## Key facts

- **NCT ID:** NCT00876486
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-02
- **Final completion:** 2013-11
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876486, "Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00876486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*